vs
Side-by-side financial comparison of PATHWARD FINANCIAL, INC. (CASH) and DYNAVAX TECHNOLOGIES CORP (DVAX). Click either name above to swap in a different company.
PATHWARD FINANCIAL, INC. is the larger business by last-quarter revenue ($276.3M vs $94.9M, roughly 2.9× DYNAVAX TECHNOLOGIES CORP). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs 26.4%, a 2.0% gap on every dollar of revenue. Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 21.0%).
Pathward Financial, Inc. is a U.S.-based banking and financial services company. It adopted its current name in 2022 after its parent, Meta Financial Group, sold the "Meta" trademark to Meta Platforms.
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
CASH vs DVAX — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $276.3M | $94.9M |
| Net Profit | $72.9M | $26.9M |
| Gross Margin | — | — |
| Operating Margin | — | 22.4% |
| Net Margin | 26.4% | 28.4% |
| Revenue YoY | — | 17.7% |
| Net Profit YoY | — | 53.0% |
| EPS (diluted) | $3.35 | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $276.3M | — | ||
| Q4 25 | $173.1M | — | ||
| Q3 25 | $186.7M | $94.9M | ||
| Q2 25 | $195.8M | $95.4M | ||
| Q1 25 | $274.8M | $68.2M | ||
| Q4 24 | $182.6M | $72.0M | ||
| Q3 24 | $179.5M | $80.6M | ||
| Q2 24 | $188.6M | $73.8M |
| Q1 26 | $72.9M | — | ||
| Q4 25 | $35.2M | — | ||
| Q3 25 | $38.8M | $26.9M | ||
| Q2 25 | $42.1M | $18.7M | ||
| Q1 25 | $75.0M | $-96.1M | ||
| Q4 24 | $30.0M | $7.0M | ||
| Q3 24 | $33.5M | $17.6M | ||
| Q2 24 | $44.9M | $11.4M |
| Q1 26 | — | — | ||
| Q4 25 | 24.6% | — | ||
| Q3 25 | 25.9% | 22.4% | ||
| Q2 25 | 24.1% | 15.1% | ||
| Q1 25 | 33.2% | -34.7% | ||
| Q4 24 | 19.8% | -2.3% | ||
| Q3 24 | 20.9% | 12.5% | ||
| Q2 24 | 27.1% | 7.0% |
| Q1 26 | 26.4% | — | ||
| Q4 25 | 20.3% | — | ||
| Q3 25 | 20.8% | 28.4% | ||
| Q2 25 | 21.5% | 19.6% | ||
| Q1 25 | 27.3% | -141.0% | ||
| Q4 24 | 16.4% | 9.8% | ||
| Q3 24 | 18.7% | 21.8% | ||
| Q2 24 | 23.8% | 15.4% |
| Q1 26 | $3.35 | — | ||
| Q4 25 | $1.57 | — | ||
| Q3 25 | $1.69 | $0.21 | ||
| Q2 25 | $1.81 | $0.14 | ||
| Q1 25 | $3.14 | $-0.77 | ||
| Q4 24 | $1.23 | $0.07 | ||
| Q3 24 | $1.34 | $0.12 | ||
| Q2 24 | $1.78 | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $157.6M | $160.2M |
| Total DebtLower is stronger | $59.5M | — |
| Stockholders' EquityBook value | $850.7M | $534.1M |
| Total Assets | $7.1B | $946.5M |
| Debt / EquityLower = less leverage | 0.07× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $157.6M | — | ||
| Q4 25 | $331.2M | — | ||
| Q3 25 | $120.6M | $160.2M | ||
| Q2 25 | $258.3M | $99.1M | ||
| Q1 25 | $254.2M | $51.7M | ||
| Q4 24 | $597.4M | $95.9M | ||
| Q3 24 | $158.3M | $119.3M | ||
| Q2 24 | $298.9M | $112.5M |
| Q1 26 | $59.5M | — | ||
| Q4 25 | $33.5M | — | ||
| Q3 25 | $33.5M | — | ||
| Q2 25 | $33.4M | — | ||
| Q1 25 | $33.4M | — | ||
| Q4 24 | $33.4M | — | ||
| Q3 24 | $33.4M | — | ||
| Q2 24 | $33.3M | — |
| Q1 26 | $850.7M | — | ||
| Q4 25 | $854.5M | — | ||
| Q3 25 | $858.0M | $534.1M | ||
| Q2 25 | $819.0M | $494.2M | ||
| Q1 25 | $814.7M | $530.9M | ||
| Q4 24 | $758.3M | $596.8M | ||
| Q3 24 | $822.5M | $681.4M | ||
| Q2 24 | $748.4M | $642.8M |
| Q1 26 | $7.1B | — | ||
| Q4 25 | $7.6B | — | ||
| Q3 25 | $7.2B | $946.5M | ||
| Q2 25 | $7.2B | $918.4M | ||
| Q1 25 | $7.0B | $945.9M | ||
| Q4 24 | $7.6B | $986.3M | ||
| Q3 24 | $7.5B | $1.1B | ||
| Q2 24 | $7.5B | $1.0B |
| Q1 26 | 0.07× | — | ||
| Q4 25 | 0.04× | — | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $33.8M |
| Free Cash FlowOCF − Capex | — | $32.6M |
| FCF MarginFCF / Revenue | — | 34.4% |
| Capex IntensityCapex / Revenue | — | 1.3% |
| Cash ConversionOCF / Net Profit | — | 1.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | $80.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $108.3M | — | ||
| Q3 25 | $303.7M | $33.8M | ||
| Q2 25 | $30.4M | $23.4M | ||
| Q1 25 | $188.3M | $-19.6M | ||
| Q4 24 | $-71.7M | $53.0M | ||
| Q3 24 | $143.1M | $19.5M | ||
| Q2 24 | $113.2M | $10.7M |
| Q1 26 | — | — | ||
| Q4 25 | $104.1M | — | ||
| Q3 25 | $300.3M | $32.6M | ||
| Q2 25 | $27.7M | $22.0M | ||
| Q1 25 | $184.7M | $-23.6M | ||
| Q4 24 | $-73.8M | $49.5M | ||
| Q3 24 | $138.8M | $18.1M | ||
| Q2 24 | $111.0M | $9.9M |
| Q1 26 | — | — | ||
| Q4 25 | 60.1% | — | ||
| Q3 25 | 160.9% | 34.4% | ||
| Q2 25 | 14.1% | 23.0% | ||
| Q1 25 | 67.2% | -34.6% | ||
| Q4 24 | -40.4% | 68.8% | ||
| Q3 24 | 77.3% | 22.5% | ||
| Q2 24 | 58.8% | 13.5% |
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | — | ||
| Q3 25 | 1.8% | 1.3% | ||
| Q2 25 | 1.4% | 1.5% | ||
| Q1 25 | 1.3% | 5.8% | ||
| Q4 24 | 1.1% | 4.8% | ||
| Q3 24 | 2.4% | 1.7% | ||
| Q2 24 | 1.2% | 1.1% |
| Q1 26 | — | — | ||
| Q4 25 | 3.08× | — | ||
| Q3 25 | 7.83× | 1.26× | ||
| Q2 25 | 0.72× | 1.25× | ||
| Q1 25 | 2.51× | — | ||
| Q4 24 | -2.39× | 7.52× | ||
| Q3 24 | 4.27× | 1.11× | ||
| Q2 24 | 2.52× | 0.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CASH
| Noninterest Income | $151.2M | 55% |
| Net Interest Income | $125.1M | 45% |
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
